No More Headaches: Drug to Treat Migraine in the Offing

By CIOReview | Wednesday, April 8, 2015

NASHVILLE, TN: Compass Point Research –clinical and translational research management and consulting firm has partnered with NDA Partners – a medical product development and regulatory strategy consultancy to develop a new combination drug to treat migraine headaches.

The drug, which is a combination of diphenhydramine (Benadryl) and trimethobenzamide (Tebamide, Tigan), the two FDA approved drugs, can be taken orally. Diphenhydramine is usually used with other combinations that include prochloperazine and metoclopramide to treat migraine and trimethobenzamide prevents nausea and vomiting. The drug when injected intramuscularly relieves pain, develops tolerability and efficacy at 24 hours compared to subcutaneous sumatriptan.

The product development team of NDA Partners includes regulatory strategy, nonclinical development, toxicology, CMC, clinical pharmacology, and experience in demonstration of clinical effectiveness of new migraine treatments.

"We are very pleased to be able to combine our extensive drug development and operational experience with world class development and regulatory experts from NDA Partners," says Lori Nesbitt, PharmD, Chief Executive Officer, Compass Point Research. "Together, we will deliver an outstanding solution for our client."